Construction and eukaryotic expression of PVAX1-hPV58mE6E7fcGB composite gene vaccine.
- Author:
He WANG
1
;
Jiyun YU
2
;
Li LI
1
Author Information
1. Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
2. Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Cancer Vaccines;
biosynthesis;
genetics;
Capsid Proteins;
biosynthesis;
genetics;
Female;
Humans;
Oncogene Proteins, Viral;
biosynthesis;
genetics;
Papillomavirus E7 Proteins;
biosynthesis;
genetics;
Papillomavirus Vaccines;
biosynthesis;
Recombinant Proteins;
biosynthesis;
genetics;
immunology;
Uterine Cervical Neoplasms;
prevention & control;
Vaccines, DNA;
biosynthesis
- From:
Journal of Biomedical Engineering
2013;30(5):1102-1107
- CountryChina
- Language:Chinese
-
Abstract:
To construct and express a composite gene vaccine for human papillomavirus 58(HPV58)-associated cervical cancer, we inserted HPV58mE6E7 fusion gene into pCI-Fc-GPI eukaryotic expression vector, constructing a recombinant plasmid named pCI-sig-HPV58mE6E7-Fc-GPI. Then we further inserted fragment of sig-HPV58mE6E7Fc-GPI into the novel vaccine vector PVAX1-IRES-GM/B7, constructing PVAX1-HPV58mE6E7FcGB composite gene vaccine. PVAX1-HPV58mE6E7FcGB vaccine was successfully constructed and identified by restriction endonuclease and sequencing analysis. Eukaryotic expression of fusion antigen sig-HPV58mE6E7-Fc-GPI and molecular ad-juvant GM-CSF and B7. 1 were proved to be realized at the same time by flow cytometry and immunofluorescence. So PVAX1-HPV58mE6E7FcGB can be taken as a candidate of therapeutic vaccine for HPV58-associated tumors and their precancerous transformations.
